Skip to main content
Clinical Trials/NCT02967718
NCT02967718
Unknown
Not Applicable

Clinical Observation of CHD Phlegm and Blood-stasis Syndrome Patients

Jingqing Hu1 site in 1 country13,000 target enrollmentSeptember 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Heart Disease
Sponsor
Jingqing Hu
Enrollment
13000
Locations
1
Primary Endpoint
all cause mortality
Last Updated
9 years ago

Overview

Brief Summary

Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Detailed Description

Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Registry
clinicaltrials.gov
Start Date
September 2016
End Date
December 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Jingqing Hu
Responsible Party
Sponsor Investigator
Principal Investigator

Jingqing Hu

Director of Institute of Basic Theory of Traditional Chinese Medicine

China Academy of Chinese Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Healthy or metabolism syndrome people
  • Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure

Exclusion Criteria

  • Any inflammation, fever, trauma, burn or operation within 1 week
  • Obstructive pulmonary disease
  • Cerebral vascular disease
  • Severe renal or hepatic dysfunction
  • Malignant neoplasms
  • Hematopoietic system disease
  • Sever mental disease

Outcomes

Primary Outcomes

all cause mortality

Time Frame: 6 months

Study Sites (1)

Loading locations...

Similar Trials